Life Sciences

  • September 04, 2026

    9th Circ. Restores Idaho Abortion Ban Enforcement, For Now

    The Ninth Circuit will allow Idaho to fully enforce its abortion ban while the state briefs its request for emergency relief from an order that blocked the ban's application in certain health-related circumstances and declared a fundamental right to some abortions under the U.S. Constitution.

  • September 04, 2026

    Lawmakers Say DOD To Divert NIH Funds For Defense Budget

    The U.S. Department of Defense is looking to "siphon" billions of dollars from the National Institutes of Health intended for biomedical research to supplement the agency's budget, according to top Democrats on the House and Senate Appropriations Committees.

  • September 04, 2026

    McKesson Owns Antitrust Claims, Not Rite Aid, Judge Finds

    A New Jersey bankruptcy judge has ruled that antitrust claims against pharmaceutical companies belong to drug distributor McKesson Corp., not the trustee overseeing Rite Aid's Chapter 11 distributions.

  • September 04, 2026

    Cooley Life Sciences M&A Atty Joins Goodwin In California

    Goodwin Procter LLP expanded its life sciences industry group with a new partner who focuses on public mergers and acquisitions from Cooley LLP.

  • September 04, 2026

    Latham, Simpson Thacher Steer Oura's Expected $2.5B IPO

    Fitness-tracking ring maker Oura has filed plans with the U.S. Securities and Exchange Commission for an initial public offering that could raise around $2.5 billion.

  • September 03, 2026

    CVS Escapes Customer's Generic Mucinex Benzene Suit

    An Illinois federal judge threw out a CVS customer's lawsuit claiming the pharmacy retailer sells an "economically worthless" generic Mucinex drug containing a known carcinogen, finding Thursday that his claims are preempted.

  • September 03, 2026

    Most Of Corteva's IP Claims Against Inari Move Along

    A Delaware federal court Thursday kept most claims alive in a case over seed intellectual property brought by Corteva Agriscience ahead of a trial set to begin later this month.

  • September 03, 2026

    Trump Admin Fights Uphill To Beat Vaccine Overhaul Suit

    A California federal judge indicated Thursday that he is likely to reject the federal government's bid to toss litigation from states challenging the Trump administration's decision to cut vaccine recommendations for American children, saying he thinks the states have standing based on the effect the change will have on their healthcare systems.

  • September 03, 2026

    Medical Biz Cites $15M Nicaragua Win To Avoid Arbitration

    A Nicaraguan medical products distributor is urging a Florida federal court to reconsider its order compelling arbitration of its dispute with GE Precision Healthcare LLC, pointing to a recent $15 million Nicaraguan court judgment that also dismisses the U.S. company's arbitration-based jurisdictional objection.

  • September 03, 2026

    Fed. Circ. Solidifies Vifor Win Over Iron Deficiency Patent

    The Federal Circuit on Thursday affirmed a lower court's decision that pharmaceutical company Vifor did not infringe a patent covering a method of making iron supplements asserted by rival Biofer.

  • September 03, 2026

    Fox Rothschild Says Adult Day Care Suit Rehashes Claims

    Fox Rothschild LLP is urging a New Jersey state court to toss claims against the firm and one of its attorneys in a complaint related to the firm's prosecution of a fraudulent loan lawsuit that led to a $65,000 sanction against the firm.

  • September 02, 2026

    Akerman Hires Consumer Protection Law Ace From Steptoe

    Akerman LLP announced on Monday it has welcomed a former Steptoe LLP attorney who brings vast experience helping clients navigate a unique, complicated landscape involving Golden State consumer protection laws and regulations, including matters related to Proposition 65.

  • September 02, 2026

    ITC Reinstates Sun Import Ban Win After Squires Intervention

    The U.S. International Trade Commission has cleared a ban against Biofrontera dermatology device imports that infringe Sun Pharmaceuticals patents, following changes at the Patent Trial and Appeal Board.

  • September 02, 2026

    Fed. Circ. Won't Bring Back Pediatric Supplement Patent

    The Federal Circuit on Wednesday declined to revive a patent covering a pediatric vitamin D supplement after some claims were found to be unpatentable by the Patent Trial and Appeal Board, finding no abuse of discretion in the board's logic.

  • September 02, 2026

    States Sue To Block Medicaid Ban On Youth Gender Care

    Twenty state attorneys general on Wednesday challenged the Trump administration's plan to halt Medicaid funding for minors' gender-affirming care, alleging the move would violate federal law and usurp congressional power over government spending.

  • September 02, 2026

    2nd Circ. Says PBM Opioid Crisis Suits Belong In Fed. Court

    Local New York governments can't keep dozens of suits alleging two of the nation's largest pharmacy benefit managers contributed to the opioid epidemic in state court, a Second Circuit panel held Wednesday, finding the litigation alleges "indivisible" federal and non-federal conduct by the PBMs.

  • September 02, 2026

    Ex-Dispensary Worker's Punitive $100K Award Cut To $75K

    A Pennsylvania federal judge cut 25% of a $100,000 punitive damages award in the case of a former dispensary worker who claimed his employer fired him for going on leave to recover from injuries he suffered in a car accident.

  • September 02, 2026

    Imported Feed Additive Is An Antibiotic, Trade Court Rules

    An animal health company's imports of a powdered feed additive should have entered the U.S. as a duty-free antibiotic, the U.S. Court of International Trade ruled Wednesday, undoing its previous classification as a preparation for animal feed from China that carried a 25% tariff.

  • September 02, 2026

    Vitamin Co. Can't Duck $1.4M Suit Over Ex-Owner's Tax Lien

    A vitamin company and its owners must face a suit by the federal government seeking $1.4 million stemming from a tax lien on a former owner's 20% interest in the company, a Connecticut federal judge ruled.

  • September 02, 2026

    Unilever, Gruns Sued Over Gummies Marketed As 'Sugar-Free'

    Unilever United States Inc. and Gruns Nutrition Inc. have been hit with class claims in New Jersey federal court alleging that they falsely labeled a line of gummies as "sugar-free" even though the nutritional supplements are sweetened with allulose, which the four suing consumers say is a sugar under federal regulations.

  • September 02, 2026

    Contractor Seeks Redo After Fed. Circ. Vacates $12.7M Award

    A software developer has urged the en banc Federal Circuit to rethink a panel's decision vacating a $12.7 million award against the federal government over unauthorized copies of the company's software, saying the panel wrongly endorsed a hypothetical negotiation between the parties to calculate damages.

  • September 02, 2026

    Mylan's Conflict Concerns Halt Antitrust Bellwether Trial Plans

    A Pennsylvania federal judge on Wednesday stayed proceedings and continued the trial date in the sprawling generic drug antitrust case after defendant Mylan alleged that the special discovery master, Saxton & Stump shareholder and former federal judge Lawrence Stengel, has a conflict of interest.

  • September 02, 2026

    Colo. Exits Pharma Group's Challenge Of Drug Discount Law

    A Colorado federal court has thrown out a pharmaceutical industry trade group's challenge of a state law requiring drug manufacturers to sell discounted drugs through contracted pharmacies, finding the group failed to show the law conflicts with federal law or controls business activity beyond Colorado's borders.

  • September 01, 2026

    Tribe Says Alaska Logging Plan Threatens Subsistence Hunts

    A U.S. government-authorized project that proposes to log thousands of acres of old-growth Alaskan forest would violate several conservation laws and interfere with Native American subsistence hunting, according to a tribal suit lodged in federal court.

  • September 01, 2026

    Mylan Cites 'Immutable Conflict' In 11th Hour Bid To Stay Trial

    Just about a week before the first trial in the sprawling generic drug price-fixing multidistrict litigation, Mylan urged a Pennsylvania federal judge to postpone the trial and stay all proceedings for at least 45 days, claiming that the special master in the case has an "immutable conflict" that impacts not just the pending trial but the entire MDL.

Expert Analysis

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

  • Opinion

    FTC's Clinical Trial Requirement Threatens Food Claim Rules

    Author Photo

    The Federal Trade Commission's general requirement for randomized controlled trials for most health-benefit claims, recently embraced by the National Advertising Review Board, lacks legal basis and endangers the existing statutory framework Congress created for marketing food and dietary supplements versus drugs, say attorneys at Keller & Heckman.

  • Drawing A Line Between Settlement Pressure And Extortion

    Author Photo

    U.S. v. Luo, pending in the U.S. District Court for the Southern District of New York, may force courts to address anew when settlement negotiations become criminal extortion, particularly in the age of easily fabricated digital evidence, says attorney Denis Kiely.

  • Series

    Founding An Autism Academy Made Me A Better Lawyer

    Author Photo

    Starting a nonprofit autism school with no building, no funding model and no guarantee that families would trust us taught me the importance of mission, patience and purpose — lessons that sharpened my practice and showed how meaningful work outside the office can make lawyers better, says Phillip Russell at Ogletree Deakins.

  • Opinion

    Rule Of Law Requires Gov't Engagement With Bar, Not Retreat

    Author Photo

    A federal agency's absence from national and local bar conferences, most recently illustrated by the U.S. Department of Justice's withdrawal from a New York City Bar Association white collar conference, disserves the bar, the government lawyers themselves and, ultimately, the administration of justice, says Muhammad Faridi at Linklaters.

  • AG Watch: Oregon's Strategic Civil Enforcement Approach

    Author Photo

    Oregon Attorney General Dan Rayfield’s recent antitrust litigation activity and proposed staffing increase are the latest in a series of structural and policy changes that signal that the state Department of Justice is taking a more aggressive approach to civil enforcement, says Keturah Taylor at Cozen O'Connor.

  • How Nasdaq's 23/5 Rule Will Alter Public Offering Strategies

    Author Photo

    The U.S. Securities and Exchange Commission's recent approval of Nasdaq's proposal to extend trading hours to 23 hours a day, five days a week, may reshape how certain public offerings are executed, particularly for confidentially marketed public offerings, say attorneys at Faegre Drinker.

  • The Paradoxical Duty To Adopt AI When You Can't Bill For It

    Author Photo

    Both billing for hours saved using artificial intelligence and preserving billable time by not adopting AI may violate rules of professional conduct, but until bar associations' ethics rules catch up to this emerging economic dilemma, firms must decide how to adjust fee structures themselves, says Ines Lassalle at Peyrot & Associates.

  • Tips For Litigating Life Sciences Investigations At The ITC

    Author Photo

    The International Trade Commission may soon become a significant battleground for life sciences companies as global intellectual property and trade disputes continue, increasing the importance of learning the ITC's unique considerations and litigation strategies, say attorneys at Crowell & Moring.

  • Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.

    Author Photo

    The recent Cannabist Chapter 15 recognition order is arguably the most significant cannabis bankruptcy development in U.S. history, providing a concrete and tested road map by which such companies with foreign parent structures can access the protective machinery of U.S. bankruptcy law, say attorneys at Saul Ewing.

  • Unsecured Synthetic Royalties May Be Returning

    Author Photo

    Recent royalty monetization deals mark a notable shift in a market that had largely moved away from unsecured synthetic royalty structures after a multiyear freeze triggered by the Mallinckrodt bankruptcy decision in 2022, which exposed a legal risk inherent to the structure, says Peter Schwartz at Covington.

  • Series

    Cow Horse Makes Me A Better Lawyer

    Author Photo

    Moving an unwilling 800-pound cow while riding a horse at high speed is exhilarating, a little unhinged and, at least for me, a surprisingly effective training ground for litigation — both demand focus, preparation over rigid planning and the willingness to act despite fear, says Ashley Zitrin at Glenn Agre.

  • Protecting AI-Driven Innovation In Life Sciences IP

    Author Photo

    Recent developments, including the U.S. Patent and Trademark Office's evolving inventorship standards, and the impact of artificial intelligence on the "person of ordinary skill in the art" standard demand that life sciences companies elevate AI patent strategy to a top priority, says Sandra Haberny at Quinn Emanuel.

  • What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.

    Author Photo

    With California poised to add welding chemicals and three medications to its list of known carcinogens under Proposition 65, businesses must assess risks from nontraditional pharmaceutical dispensing, occupational and environmental exposures to welding operations, and downstream exposures from the manufacture of both types of substances, says Gregory Berlin at Alston & Bird.

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.